Epilepsy

Editor's Choice

Study validates switch to generic anticonvulsants

Switching from branded to generic drugs for epilepsy did not cause increased incidents or utilization changes among patients, according to new study results.

LATEST ARTICLES

Chronic pain, epilepsy drugs approved

FDA has approved tapentadol extended release tablets for pain management and ezogabine for use as an add-on medication to treat epilepsy.

Ezogabine (Potiga): Oral potassium channel opener indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older

New molecular entity: Ezogabine was FDA approved for use as an add-on medication to treat partial-onset seizures associated with epilepsy in adults.

FDA approves clobazam to treat severe type of seizures

FDA has approved clobazam (Onfi, Lundbeck and Catalent Pharma Solutions) as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.

New Tool: Rx Adherence Predictor

Now you can determine in advance the likelihood of a patient filling and staying on their medications. This tool can support your ability to prioritize and target patients who may benefit from counseling about the importance of maintaining your prescribed drug regimen.

Vigabatrin (Sabril): An antiepileptic drug approved for the treatment of refractory complex partial seizures in adults and spasms in infants

New molecular entity: Vigabatrin (Sabril) was approved as an adjunctive treatment of refractory complex partial seizures in adults who have responded inadequately to several alternative treatments; and as monotherapy for pediatric patients with infantile spasms.